ES2099764T3 - Formulacion a base de diltiazem. - Google Patents

Formulacion a base de diltiazem.

Info

Publication number
ES2099764T3
ES2099764T3 ES92108361T ES92108361T ES2099764T3 ES 2099764 T3 ES2099764 T3 ES 2099764T3 ES 92108361 T ES92108361 T ES 92108361T ES 92108361 T ES92108361 T ES 92108361T ES 2099764 T3 ES2099764 T3 ES 2099764T3
Authority
ES
Spain
Prior art keywords
diltiazem
formulation based
diltiacem
formula
pearls
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92108361T
Other languages
English (en)
Inventor
Dennis L Hendrickson
Dan C Dimmitt
Mark S Williams
Paul F Skultety
Michael J Baltezor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Hoechst Marion Roussel Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Inc filed Critical Hoechst Marion Roussel Inc
Application granted granted Critical
Publication of ES2099764T3 publication Critical patent/ES2099764T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRESENTE INVENCION ESTA DIRIGIDA A UNA FORMULA DE DILTIACEM ADECUADA PARA LA ADMINISTRACION DE UNA AL DIA. LA FORMULA CONTIENE UNA MEZCLA DE PERLAS DE DILTIACEM CON DOS PERFILES DE DISOLUCION DIFERENTES.
ES92108361T 1991-05-20 1992-05-18 Formulacion a base de diltiazem. Expired - Lifetime ES2099764T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70256791A 1991-05-20 1991-05-20

Publications (1)

Publication Number Publication Date
ES2099764T3 true ES2099764T3 (es) 1997-06-01

Family

ID=24821752

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92108361T Expired - Lifetime ES2099764T3 (es) 1991-05-20 1992-05-18 Formulacion a base de diltiazem.

Country Status (17)

Country Link
EP (1) EP0514814B1 (es)
JP (1) JP3804029B2 (es)
KR (1) KR100244010B1 (es)
AT (1) ATE147982T1 (es)
AU (1) AU653223B2 (es)
CA (1) CA2068980A1 (es)
DE (1) DE69216910T2 (es)
DK (1) DK0514814T3 (es)
ES (1) ES2099764T3 (es)
FI (1) FI922270A7 (es)
GR (1) GR3022927T3 (es)
IE (1) IE921603A1 (es)
IL (1) IL101896A (es)
NO (1) NO921973L (es)
NZ (1) NZ242730A (es)
TW (1) TW265267B (es)
ZA (1) ZA923474B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100221695B1 (ko) * 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
US7070806B2 (en) 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
EP0717625B1 (en) * 1993-09-08 2002-06-12 Pharmacy and Therapeutic Advisory Consultancy Ltd. A method of treating liver disease and like indications with vasodilating agents
US5854233A (en) * 1993-09-08 1998-12-29 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US6174917B1 (en) 1993-09-08 2001-01-16 Pharmacy And Therapeutic Advisory Consultancy Ltd. Method of treating liver disease and like indications with vasodilating agents
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
FR2754710B1 (fr) * 1996-10-22 1998-12-31 Prographarm Lab Procede de preparation d'une forme pharmaceutique multiparticulaire a liberation controlee plurisequentielle
US6162463A (en) * 1997-05-01 2000-12-19 Dov Pharmaceutical Inc Extended release formulation of diltiazem hydrochloride
US6306438B1 (en) 1997-07-02 2001-10-23 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
FR2771292B1 (fr) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
WO1999038507A1 (en) * 1998-01-30 1999-08-05 David George Le Couteur Reversal and prevention of clinically significant aspects of aging through oral use of hepatic artery vasodilator and other agents which increase hepatic oxygenation
IL142896A0 (en) * 1998-11-02 2002-04-21 Elan Corp Plc Multiparticulate modified release composition
CA2447008A1 (en) * 2001-04-05 2002-10-24 Collagenex Pharmaceuticals, Inc. Controlled delivery of tetracycline compounds and tetracycline derivatives
JP5072364B2 (ja) * 2003-11-25 2012-11-14 スミスクライン ビーチャム （コーク） リミテッド カルベジロール遊離塩基、カルベジロール塩、無水形態またはその溶媒和物、対応する医薬組成物、制御放出処方および治療またはデリバリー方法
US7866376B2 (en) 2007-10-29 2011-01-11 Fu Zhun Precision Industry (Shen Zhen) Co., Ltd. Heat dissipation device with U-shaped and S-shaped heat pipes
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN114425046B (zh) * 2021-12-16 2023-10-20 南通联亚药业股份有限公司 一种盐酸地尔硫卓缓释胶囊

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
JPS6215A (ja) * 1985-02-26 1987-01-06 Fujisawa Pharmaceut Co Ltd ２−ニトロオキシメチル−６−クロロピリジンまたはそのβ−シクロデキストリン包接化合物含有持続性製剤
US4826688A (en) * 1985-11-13 1989-05-02 501 Elan Corporation PLC. Controlled absorption pharmaceutical formulation
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
DK173505B1 (da) * 1987-02-20 2001-01-15 Pharmatec Internat S R L Fremgangsmåde til fremstilling af en diltiazempellet med langsom afgivelse og anvendelse af således fremstillede pelleter t
DE3856555T2 (de) * 1987-10-16 2004-04-29 Elan Corp. Plc Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
SE8902699D0 (sv) * 1989-08-09 1989-08-09 Lejus Medical Ab Diltiazem containing pharmaceutical compositios

Also Published As

Publication number Publication date
DE69216910T2 (de) 1997-05-22
FI922270L (fi) 1992-11-21
DE69216910D1 (de) 1997-03-06
AU653223B2 (en) 1994-09-22
DK0514814T3 (da) 1997-02-10
AU1632692A (en) 1992-11-26
NO921973L (no) 1992-11-23
KR100244010B1 (ko) 2000-03-02
IL101896A0 (en) 1992-12-30
FI922270A7 (fi) 1992-11-21
CA2068980A1 (en) 1992-11-21
JP3804029B2 (ja) 2006-08-02
TW265267B (es) 1995-12-11
NZ242730A (en) 1994-09-27
KR920021150A (ko) 1992-12-18
GR3022927T3 (en) 1997-06-30
ATE147982T1 (de) 1997-02-15
NO921973D0 (no) 1992-05-19
EP0514814A1 (en) 1992-11-25
ZA923474B (en) 1993-01-27
FI922270A0 (fi) 1992-05-19
IE921603A1 (en) 1992-12-02
IL101896A (en) 1996-08-04
JPH05178747A (ja) 1993-07-20
EP0514814B1 (en) 1997-01-22

Similar Documents

Publication Publication Date Title
ES2090713T3 (es) Sales organicas de n,n'-diacetil-cistina.
ES2138622T3 (es) Derivados de mercaptoacetilamido piridazo(1,2-a)(1,2)diazepina utilizados como inhibidores de encefalinasa y eca.
ES2114870T3 (es) Nuevos derivados de mercaptoacetilamida utiles como inhibidores de encefalinasa y eca.
FI945311L (fi) Oksibutyniinin transdermaalinen annostelu
MX9304581A (es) Desoxitaxoles y composiciones farmaceuticas que los contienen
ES2096091T3 (es) Nuevas composiciones a base de derivados de la clase de los taxanos.
NO921973L (no) Diltiazen-formulering
MX9701342A (es) Formulacion cosolvente de tirilazad para administracion parenteral.
ES2101230T3 (es) Nuevos derivados de sustancias anti-inflamatorias, analgesicas y/o antipireticas no estereoideas, su uso y formulaciones farmaceuticas que las contienen.
ES2184131T3 (es) Derivados de benzamidina y su utilizacion como medicamentos con efecto antagonista de ltb4.
ES2134801T3 (es) Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso.
MX9302116A (es) Compuestos azabiciclo.
DK0415766T3 (da) Anvendelse af retinoider til reversering af glucocorticoid fremkaldt hudatrofi
ES2126684T3 (es) Utilizacion de derivados de acidos carboxilicos aromaticos para la preparacion de medicamentos.
ES2043665T3 (es) 6,11-dihidro-11-(4-piperidiliden)-5h-benzo-(5,6)-ciclohepta-(1,2-b)-piridinas y composiciones y metodos de uso.
ES2045484T3 (es) Nuevos derivados de la vitamina d: aplicaciones terapeuticas y a las dosificaciones de los metabolitos de la vitamina d.
ES2171722T3 (es) Nuevos derivados de la 5-o-desosaminil-6-o-metil-eritronolida a, su procedimiento de preparacion y su aplicacion a la preparacion de productos biologicamente activos.
MX9204342A (es) Indoles.
MX9303572A (es) Inhibidores de proteasa del sindrome de inmunodeficiencia humana, procedimiento para su preparacion y formualcion farmaceutica que los contiene.
SV1998000013A (es) Derivados de 5-aroilnaftaleno ref.-ran 4070\115
ES2195158T3 (es) Amidas de alfa-aminoacidos, su preparacion y el uso terapeutico de las mismas.
ES2077473T3 (es) Nuevos compuestos tiocromanicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
MX166685B (es) Proceso para la preparacion de alcanosulfonamidas y arenosulfonamidas
FI941625L (fi) Trietanoliamiinituoteseoksen käyttö
MX9302878A (es) Procedimiento para la preparacion de un diaminodiol substituido.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 514814

Country of ref document: ES